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Backgrounds: Magnesium has been known for its antioxidative and antiinflammatory properties in many studies.
In this study two dosing regimens of magnesium were compared with a placebo control group in order to
investigate safety and efficacy of high doses of intravenous magnesium sulfate infusion on critically ill trauma
patients. Inflammatory and oxidative factors were measured in this trial.
Methods: 45 trauma patients with systemic inflammatory response syndromes (SIRS) were randomly assigned into
2 treatment and one placebo groups. The high dose group received 15 g MgSO4, low dose group received 7.5 g
of MgSO4 over 4 hour infusion, and placebo group received saline alone. The initial and post magnesium sulfate
injections levels of tumor necrosis factor alpha (TNF-α), total antioxidant power and lipid peroxidation were
measured after 6, 18 and 36 hours. The pre-infusion along with 6 and 36 hour level of microalbuminuria were
also determined.
Results: Repeated measurements illustrated that there was no significant difference in TNF-α, total antioxidant
power and lipid peroxidation levels among groups during the period of analysis. The microalbuminuria at 36 hour
post infusion of high dose group was lower than that of control group (p = 0.024). Patient’s mortality (28 day) was
similar among all treatment groups. Both magnesium infusion groups tolerated the drug without experiencing
any complications.
Conclusion: No evidence for antioxidative and antiinflammatory effects of magnesium in traumatic SIRS positive
patients was found. Magnesium in high doses may be recommended for traumatic patients with SIRS status to
prevent microalbuminuria.
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Magnesium is one of the four most common electrolytes
in human body which is an essential co-factor in more
than 300 enzymatic reactions. It is involved in many vital
processes, such as cardiac excitability [1], transmem-
brane ion flux, and neurotransmitter release and gating
of calcium ion channels [2]. In many respects mag-
nesium serves as a physiological antagonist of calcium
[3] and this is a very important theoretical role for* Correspondence: mojtahed@sina.tums.ac.ir
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reproduction in any medium, provided the ormagnesium in critical care medicine [4]. Calcium has
a defined effect in inflammatory responses, cytokine
release and programmed cell death [5]. Magnesium defi-
ciency is common among hospitalized patients (7-11%)
and it has been found in 20-60% of intensive care unit
(ICU) admitted patients [6]. In near half of electrolyte
abnormalities, hypomagnesaemia is found to be a co-
morbid factor [7] which indicates its important role in
ICU patients [4]. Microalbuminuria is defined as excre-
tion of albumin in small amounts (between 30 and
300 mg/day) that indexed for reliability as microalbumin
to creatinine ratio (MACR) [8]. In the past few years,
microalbuminuria is utilized for determining severity ofral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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sized that increasing pro-inflammatory and inflamma-
tory factors will lead to increase in permeability of
endothelium and consequent increase of albumin excre-
tion through kidneys.
The relationships between oxidative stress, inflamma-
tion, proteinuria and hypomagnesaemia have been evalu-
ated in previous animal and human studies [3,10-12]
and cultured human cells [13]. However, we have not
came across any study which was conducted in normo-
magnesemic patients, therefore the effectiveness of mag-
nesium as a therapeutic agent in critical care medicine
has not been validated [12,14]. It is hypothesized that
high doses of magnesium infusion would be effective
and safe for the management of oxidative stress and in-
flammation following SIRS/trauma.
Methods
Study design and setting
This randomized clinical trial study was conducted dur-
ing 14 months at a University teaching hospital ICU.
Block randomization method used to randomize the
patient and both patient and researcher were blinded
and a third party decides the treatment group designated
to patients based on a randomization table.
Patient population
The study procedure was approved by the University
ethics committee with code number (87-03-33-7752)
according to the declaration of Helsinki. Patients or their
relatives were informed of the study and a written con-
sent was obtained from each individual. Severely ill
patients who were admitted for multiple trauma with an
Acute Physiology And Chronic Health Evaluation (APA-
CHE II) score of more than 18 accompanied by SIRS cri-
teria [15]. A normal ionized serum magnesium (isMg)
level (0.75 < isMg < 0.95 mmol/l) [4] and albumin con-
centration (40–60 g/l) were the other criteria for accept-
ance of patients into clinical study pool.
The patient exclusion criteria were conditions that
may cause pathological microalbuminuria (creatinine
>1.5 mg/dl, metabolic syndrome and diabetes mellitus
[16]). Patients with such conditions either before admit-
ting or during stay at ICU were excluded from the study.
Patients who had taken drugs which are known as endo-
thelial active drugs (like angiotesin-converting-enzyme,
C reactive proteins, corticosteroids and statins) [17], pre-
vious magnesium intake, hematologic diseases, neuro-
muscular disease, pregnancy, severe sepsis and septic
shock also were also excluded.
Patients’ ionized serum magnesium concentration was
based for determination of magnesium status [18] and
all of the patients considered not having serum hyper or
hypomagnesaemia at the time of study enrollment. Theionized serum magnesium concentration was measured
with ion selective electrodes by Stat Profile Critical
Care Xpress analyzer (NOVA biomedical, Waltham,
Massachusetts, USA).
Before enrollment a 5 ml blood sample was taken from
a central catheter with a heparinized acid washed syr-
inge. This sample was centrifuged in an acid washed test
tube and serum derived from blood was used to assess
isMg in sample. Before starting infusion and after 6, 18
and 36 hour blood samples were taken in order to meas-
ure TNF-α, total antioxidant power and lipid peroxidation.
Total antioxidant power was measured by ferric redu-
cing ability of plasma (FRAP) and the extent of lipid
peroxidation was determined with thiobarbituric acid
(TBA) method called TBA reactive substances (TBARS)
as both were described in our previous paper [1]. TNF-α
was assessed with Enzyme-Linked ImmunoSorbaent
Assay (ELISA) kit obtained from (BenderMed Systems,
Austria) according to manufacturer manual. Creatinine
in urine samples were measured with an immunoassay
method utilizing BT3500 analyzer (Biotecnica instru-
ments, Italy) by using Jaffe method [19] according to the
manufacturer’s brochure. Detection range was >3 mg/L.
MACR was determined by ratio between urinary albu-
min and creatinine concentration. All the samples were
tested twice in order to achieve a higher grade of preci-
sion. The average of both results were recorded and uti-
lized in analysis.
Patient’s demographic characteristics were recorded
at the admission to ICU. The APACHE II scores for def-
inition of severity of illness, and Sequential Organ Fail-
ure Assessment (SOFA) score for organ failure were
calculated in the first day of admission. Therapeutic
intervention scoring system (TISS) score was used to
evaluate equal medical treatment among study groups.
Deep tendon reflexes were checked hourly during infu-
sion and routinely in the first three days of study. All the
patients had urinary catheters and were under mechan-
ical ventilation.
Patients were randomized in this study. High and
moderate dose group received 70 or 35 ml of 20%
MgSO4 solutions, respectively. This amount is equiva-
lent to 15 or 7.5 g of magnesium sulfate for high or
moderate group which was diluted into 1000 ml of NaCl
(0.9% v/v) and infused in 4 hours.
Three 5 ml midstream urine samples were obtained
during the first two days of study. The samples were
taken at the time of enrollment (0 hour), 2, 6 and
36 hours post infusion. The study period proceeded for
28 days.
Statistical analysis
Data are presented as mean with standard errors. Univari-
ate comparisons of baseline characteristics were performed
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used to test differences in survival among groups. Two-
way analysis of variance was applied for comparing the
repeated measurements of microalbumin levels among
groups with multiple comparisons (Scheffe’s test) for
each time period. A p value of less than 0.05 has been
considered statistically significant. Values for microalbu-
min were log transformed to obtain proportionally con-
stant variation and normally distributed data.
Results
Population Characteristics
53 trauma patients enrolled in this study and 8 were
excluded. Four of these patients (2 moderate doses, 1
high dose and 1 control) dropped out due to their pro-
gression to acute renal injury, 1 patient died during
study and 3 patients had developed severe sepsis mani-
festations. The patients (n = 45) were randomly divided
into three groups. The two experimental groups con-
sisted of high and medium level doses of magnesium.
The remaining 15 patients were included in a placebo
control group. Patient’s demographic characteristics and
clinical manifestation are summarized in Table 1. Sub-
jects had no statistical differences in their age, sex, TNF-α,
FRAP, TBARS, MACR, APACHE II and SOFA scores at
the time of enrollment into the study.
It is important to note that patients ionized serum
magnesium concentration was based for determination
of magnesium status [18]. This method is considered to
be the most accurate (Table 1). All the patients’ baseline
serum ionized magnesium concentration was in normal
range at the start point of the study.
Effect of magnesium on oxidative & inflammatory factors
The TNF alpha levels remained steady for the control
group at all time points. There was only a slight (statisti-
cally insignificant) decrease in TNF-α at 36-hour time
point for both experimental groups (Table 2), suggesting
that the blood retained its reductive characteristics. TheTable 1 Demographic data, Scoring systems and MACR at the
Control
Age(years) 49.33333 ± 5.30
sex Male 13 (86%)
Female 2 (14%)
Mortality rate 6 (40%)
APACHE II(0 h) 21.06 ± 0.69
SOFA(0 h) 8.33 ± 0.30
TNFα (pg/ml)(0 h) 36.37 ± 11.77
TBARS (μM)(0 h) 3.89 ± 0.65
FRAP (μM) 402.44 ± 65.33
MACR(0 h)* 30.21 ± 5.69
APACHE = Acute Physiology and Chronic Health Evaluation, SOFA = Sequential Orgalevel of FRAP remained steady for all the groups. How-
ever, TBARS level for the high dose group demonstrated
a considerable drop in readings at 36 hour (3.0 ± 1.0)
when it was compared to the 18 hour readings (3.6 ±
1.2) for the high dose group. The reduction in TBARS
level is an indication of the positive effect of high dose
of magnesium on traumatic patients who were positive
for systemic inflammatory response syndromes (SIRS)
normomagnesemic status (Table 2).
There were no significant difference in levels of TNF- α
and TBARS. Another noticeable change was microalbumi-
nuria, at 36 hours post magnesium infusion in high dose
group which was determined to be statistically lower than
the control group (p = 0.024)(Figure 1). The trends of
other mentioned anti inflammatory and oxidative factors
proved our hypothesis on existence of lower levels of
MACR over time between high dose infusion and placebo
groups.
Outcome
A trend toward mortality reduction was found in high
dose magnesium recipients although this difference was
not statistically significant. Patients tolerated MgSO4 in-
fusion very well with no significant difference between
treatment and placebo groups (p = 0.61) and no serious
adverse reaction were reported, except for 2 cases of
hypermagnesaemia in the high dose group which did not
have any clinical consequences.
Discussion
This study demonstrate that high doses of magnesium
reduce microalbuminuria in traumatic critically ill
patients at 36 hour post infusion. Although no signifi-
cant difference observed among trends, there was a posi-
tive trend toward better outcomes in treatment groups
in total antioxidant power, lipid peroxidation and TNF-α
between treatment and placebo groups.
Microvascular changes induced by nitric oxide (NO)
and other proinflammatory factors and their interactionbeginning of the study
moderate dose High dose Sig.
39.86667 ± 5.51 48.33333 ± 5.29 NS
13 (86%) 13 (86%) NS
2 (14%) 2 (14%) NS
7 (46.7%) 5 (33.3%) NS
21.20 ± 0.56 21.26 ± 0.58 NS
8.53 ± 0.44 8.20 ± 0.29 NS
34.16 ± 9.99 32.71 ± 11.42 NS
4.27 ± 1.44 3.76 ± 1.32 NS
399.61 ± 71.83 448.87 ± 85.03 NS
27.59 ± 5.35 29.53 ± 5.35 NS
n Failure Assessment, MACR =microalbumin to creatinine ratio. * mg/mmol.







TNF-α pg/ml ± SD 0 h 36.0 ± 12.1 37.0 ± 12.2 38.1 ± 10.7
6 h 37.4 ± 13.2 34.5 ± 8.1 35.6 ± 15.4
18 h 35.6 ± 11.6 36.38 ± 10.8 30.1 ± 7.0
36 h 36.3 ± 10.9 28.6 ± 6.5 26.9 ± 7.9
FRAP μM± SD 0 h 421. ± 54.5 412.3 ± 69.9 424.7 ± 71.4
6 h 397.1 ± 69.0 398.7 ± 73.0 427.5 ± 74.6
18 h 407.7 ± 82.2 401.8 ± 90.7 452.7 ± 90.8
36 h 383.4 ± 51.4 385.5 ± 53.8 490.5 ± 92.5
TBARS μM± SD 0 h 4.1 ± 0.7 4.3 ± 1.7 4.4 ± 1.0
6 h 3.7 ± 0.5 4.4 ± 1.0 3.9 ± 1.5
18 h 3.9 ± 0.7 4.2 ± 1.1 3.6 ± 1.2
36 h 3.7 ± 0.4 4.1 ± 1.4 3.0 ± 1.0
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patients. Endothelial cells could be injured through
inflammatory response and cause an increase in capillary
permeability particularly in glomerular vessels [8] which
induces kidneys to undergo transient proteinuria. The
deleterious scale of these changes can be measured by
increased levels of microalbuminuria [8]. The population
enrolled in this study was homogenous and consisted of
neurotraumatic critically ill only. The purpose of this
study is to evaluate the efficacy and rational of magne-
sium infusion on neurotraumatic patients. In traumatic
condition, an energy depletion dilemma emerges in
cellular level. The consequence of this depletion is
reduction in activity of transmembrane calcium ion
transport channels which leads to distorted ion balance
and permeability changes. Membrane permeability
changes cause calcium influx in cells, which results in
many deleterious reactions such as alternation of ade-
nosine triphosphate (ATP) production in mitochondria,
overproduction of reactive oxygen species (ROS), NOFigure 1 Changes in microalbumin/creatine in urine samples of contr
by hours. * p < 0.05 vs high dose magnesium group.generation and release of proinflammatory factors [1,2].
Magnesium could serve as antagonist of calcium to
inhibit these harmful effects [3] in traumatic patients.
In previous animal studies it was demonstrated that
hypomagnesaemia can cause systemic inflammatory
syndrome [12]. Magnesium deficiency opens N-methyl-
D-aspartate (NMDA) calcium channels and activates
nuclear factor-kappa B (NF-kB) as primary mechanism
of inflammation [11]. However, in this study after mag-
nesium infusion, the levels of TNF-α, total antioxidant
power and lipid peroxidation did not demonstrate any
significant change at various periods of analysis. There-
fore, administration of magnesium salt did not display
any anti-inflammatory activities in critically ill patients
with normal levels of this ion. Effect of body magnesium
levels (plasma, erythrocyte and urine) and its association
with microalbuminuria has been previously studied on
type 1 diabetic patients [20]. A negative relation between
erythrocyte magnesium level and microalbuminuria was
observed suggesting hypomagnesaemia as a risk factorol group vs. moderate dose and high dose magnesium group
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was suggested that hypomagnesaemia is an independent
risk factor for microalbuminuria in type two diabetic
patients [20]. In the present study there has been a lag
about 48–72 hour between hospital and ICU admission
that might be the time that most critical changes in level
of TNF-α and oxidative marker occurred and thus less
significant changes were observed subsequently. As we
mentioned in previous study with cytokines determin-
ation of cutoff point for cytokine measurement in ethnic
populations remained unclear and problematic [21]. Our
previous study verified that N-acetylcysteine performs as
a free radical scavenger and an anti-inflammatory agent
and improves microalbuminuria in acute respiratory dis-
tress syndrome patients [22]. It has been illustrated that
severity of microalbuminuria has a direct relationship
with mortality and morbidity rates [9,16]. Although,
no significant change in TNF-α and oxidative factors
showed up in the study time window, the change in
microalbumin suggests that inflammation has been
reduced in the high dose treatment subjects. In order to
omit the bias of hypomagnesaemia effect on proteinuria
[20], patients with normal levels of serum magnesium
were allowed to be enrolled in this clinical study. Mag-
nesium total serum concentration is the most studied
laboratory parameter and considered poorly related to
cellular status of magnesium in the patient’s body.
Magnesium loading test or ionized serum magnesium
concentration is used for evaluation of magnesium suffi-
ciency in the body [23]. Magnesium loading test was not
utilized for evaluation of magnesium status in this study
because patients received a large dose of magnesium
before enrollment in the study and the result would be
compromised and unreliable. Therefore, ionized serum
magnesium test was utilized in order to establish magne-
sium status. Ionized serum magnesium test has been
applied to establish magnesium status instead of magne-
sium loading test due to limitation of previous magnesium
intake. In this study, the serum albumin concentration
was assessed prior to the evaluation of magnesium status.
High levels of albumin may interfere with ionized serum
magnesium test [23] and may negatively impact the accur-
ate evaluation for microalbuminuria.
Although, management of patients in ICU is somehow
complicated and dependent of the status of each patient
[24], it was decided to use an established protocol as a
base amount for moderate dose of magnesium that was
safe over the years in ICU [25]. Two fold of that dose
has been assumed as high dose of magnesium for this
study. The positive effect of magnesium dosing in critic-
ally ill patients is under debate and the results are
controversial. Determination of a specific dose was dif-
ficult because compensation for magnesium depletion
was not the aim of this study. The normomagnesemicpopulations have never been studied before to the extent
of our knowledge. Therefore, clinically significant results
would be due to the theoretical role of magnesium.
There were no significant difference among groups dur-
ing time, but after 36 hours, the MACR in high dose
magnesium group was significantly lower than control
group (Figure 1).
Mild bradycardia and hypotension were the only side
effects observed in patients who received magnesium.
Therefore we suggest that magnesium doses as high as
the ones used in this study are relatively safe for infusion
of critically ill patients. However magnesium therapy
should be considered in special populations. Magnesium
is generally cleared by kidneys and magnesium therapy
in higher doses should be administered with more
caution in patients with any risk of renal failure.
Administration of magnesium as a therapeutic agent is
not a common approach, but it is routinely employed to
correct the hypomagnesemic state. In this study magne-
sium sulfate infusion was administered as an anti-
inflammatory therapeutic agent and some optimistic
results were obtained. In order to obtain a more defini-
tive conclusion, another more elaborated clinical trial is
recommended.
There was a beneficial trend toward high magnesium
load where we left the study (Figure 1). The number of
subjects and the duration of study were limited in this
trial. The results could not be generalized to the popula-
tion in this condition, but it is recommended to conduct
more studies with longer duration and greater sample
size. It is also recommended to infuse magnesium in
longer duration and more divided intervals.
Conclusion
We did not find conclusive evidence for antioxidative
and antiinflammatory effects of magnesium in traumatic
SIRS positive patients. However, high dose magnesium
might be recommended as a safe option for preventing
microalbuminuria in traumatic patients with SIRS criteria.
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